ESS vs REGN · P/E 31, rev $1.89B vs P/E 14, rev $14.34B
Essex Property Trust Inc (ESS) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Essex Property Trust Inc (ESS) is a reit - residential company listed on NYSE.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported ESS revenue for 2025-12-31 was $1.89B. Net income was $702.8M. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. ESS currently screens at market cap $18.91B and trailing P/E 30.9.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
ESS currently screens at market cap $18.91B and trailing P/E 30.9. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the ESS and REGN stock pages for the full models.
Not investment advice.